The sanctity of peer review is under scrutiny again. Last month Pfizer filed a motion in federal court to force the New England Journal of Medicine to turn over confidential peer review documents for two of their products, Celebrex and Bextra. The company said they need the reviews to help defend themselves in lawsuits involving the two painkillers. But linkurl:Donald Kennedy,; editor-in-chief of Science, writes in an linkurl:editorial; in this week's issue of the journal that the move undermines confidential peer review. Pfizer attorneys said that some of the plaintiffs have cited the literature published in the NEJM on Celebrex and Bextra, and they should be able to search through the peer review communications for material to help strengthen their defense. In a statement Emailed to the Wall Street Journal linkurl:Health Blog,; the company said that "a number of authors and/or medical and scientific journals" were subpoenaed to release...
The Scientist

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?